C
19.64
-1.55 (-7.31%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Bullish |
| Biotechnology (Global) | Bullish | Bullish | |
| Stock | Cassava Sciences, Inc. | - | - |
|
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer’s disease dementia. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Gallacher Capital Management Llc | 31 Dec 2023 | 581,606 |
| 52 Weeks Range |
12.32 - 32.10
|
|
| High | 124.00 (HC Wainwright & Co., 531.36%) | Buy |
| Median | 124.00 (531.36%) | |
| Average | 124.00 (531.36%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 05 Mar 2024 | 124.00 (531.36%) | Buy | 21.41 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BARRY RICHARD | - | - | 0 | 0 |
| KUPIEC JAMES WILLIAM | - | - | 0 | 0 |
| ROBERTSON SANFORD | - | - | 0 | 0 |
| Aggregate Net Quantity | 0 | |||
| Aggregate Net Value ($) | 0 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ROBERTSON SANFORD | Director | 26 Apr 2024 | Option execute | 69,000 | - | - |
| BARRY RICHARD | Director | 23 Apr 2024 | Option execute | 176,085 | - | - |
| KUPIEC JAMES WILLIAM | Officer | 18 Apr 2024 | Option execute | 1,500 | - | - |
| Date | Type | Details |
|---|---|---|
| 01 May 2024 | Announcement | Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ |
| 15 Apr 2024 | Announcement | Redemption Date Announced for Warrants |
| 25 Mar 2024 | Announcement | Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials |
| 04 Mar 2024 | Announcement | Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference |
| 28 Feb 2024 | Announcement | Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates |
| 07 Feb 2024 | Announcement | No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |